# A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)

> **NCT01713582** · PHASE1 · COMPLETED · sponsor: **Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 141 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Diffuse Large B-cell Lymphoma
- Acute Lymphoblastic Leukemia
- Multiple Myeloma

## Interventions

- **DRUG:** OTX015/Birabresib

## Key facts

- **NCT ID:** NCT01713582
- **Lead sponsor:** Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-14
- **Primary completion:** 2017-01-20
- **Final completion:** 2017-01-20
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2021-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01713582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01713582, "A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01713582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*